Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Filip Rázga

CEO

Selecta Biotech SE

Bratislava, Slovakia

2 profile visits

I am the CEO of Selecta Biotech SE, a European joint-stock company founded with the ambition to implement a new generation of oligonucleotide therapeutics in clinical practice, with the aim of achieving the desired therapeutic effect without side effects.

My organisation

Selecta Biotech SE is a European joint-stock company founded with the ambition to improve patient health care through safe therapeutic solutions – implement a new generation of oligonucleotide therapeutics in clinical practice with the aim of achieving the desired therapeutic effect without side effects. Despite the massive global spend on biology-driven drug discovery, tackling side effects and adverse events resulting from drug promiscuity is one of the greatest challenges faced today. We have proposed an original solution to this persistent problem and hold a patented technology and relevant know-how in R&D of tailor-made oligonucleotide therapeutics that provide exclusive therapeutic intervention against their molecular targets thereby eliminating treatment-induced toxicity. We are committed to encouraging the translation of these discoveries into new treatments and pursue milestone-driven projects. Based on this proprietary platform, named ESiNAR-X®, multiple therapeutic leads have been proposed for various diagnoses and are currently in different stages of preclinical and clinical development.
Read more

About me

Dr Razga has 25+ years of professional experience in oncology, with a biotechnology focus within the last decade. He is trained in Physical and Biomolecular chemistry with primary research interest in RNA structure and function. After working at the National Centre for Biomolecular Research (CZ) he became an associate at Bowling Green State University (Ohio, USA). Dr Razga then accepted a position at the Center of Molecular Biology and Gene Therapy (CZ), and later became a team leader at the Slovak Academy of Sciences with research focus in anticancer therapy.

Dr Razga Holds multiple awards including the Award of the Ministry of Education, Youth and Sports of the Czech Republic and the Award of the Slovak Academy of Sciences and had been the recipient of the prestigious international Marie Skłodowska-Curie Fellowship.

Social media

Marketplace (3)

  • Project cooperation

    ASC1R

    ASC1R is an oligonucleotide-based therapeutic developed on the ESiNAR-X platform, targeting the SARS-CoV-2 RNA virus and intended for critically ill patients requiring intensive care to rapidly inhibit viral replication.

    Author

    Filip Rázga

    CEO at Selecta Biotech SE

    Bratislava, Slovakia

  • Project cooperation

    ASP210

    ASP210 is a therapeutic oligonucleotide leveraging the ESiNAR-X platform to target BCR-ABL1 mRNA in patients with chronic myeloid leukemia who are resistant or refractory to TKI therapy.

    Author

    Filip Rázga

    CEO at Selecta Biotech SE

    Bratislava, Slovakia

  • Project cooperation

    ASPER2

    ASPER2 is a therapeutic oligonucleotide based on the ESiNAR-X platform, intended for patients with gradually progressive chronic kidney disease accompanied by renal fibrosis.

    Author

    Filip Rázga

    CEO at Selecta Biotech SE

    Bratislava, Slovakia